Jump to main content
Jump to site search

Issue 34, 2018
Previous Article Next Article

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Author affiliations


Mitoxantrone (MTO) is a topoisomerase II inhibitor which has been used to treat various forms of cancer either as a solo chemotherapy regimen or as a component in cocktail treatments. However, as with other anti-neoplastic agents, MTO has severe cardiac side effects. Therefore, a drug delivery approach holds promise to improve the safety and applicability of this chemotherapy. Here, we report the application of a plant virus-based nanotechnology derived from tobacco mosaic virus (TMV) as a delivery vehicle for MTO towards cancer therapy. TMV is a high aspect-ratio, soft-matter nanotube with dimensions of 300 × 18 nm and a 4 nm wide channel. The surface chemistry of the interior and exterior TMV surfaces is distinct and we established charge-driven drug loading strategies to encapsulate therapeutics for drug delivery. We demonstrate effective MTO loading into TMV yielding ∼1000 MTO per TMV carrier. The treatment efficacy of MTO-loaded TMV (MTOTMV) was assessed in in vitro and in vivo models. In vitro testing confirmed that MTO maintained its efficacy when delivered by TMV in a panel of cancer cell lines. Drug delivery in vivo using a mouse model of triple negative breast cancer demonstrated the superior efficacy of TMV-delivered MTO vs. free MTO. This study demonstrates the potential of plant virus-based nanotechnology for cancer therapy and drug delivery.

Graphical abstract: Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Back to tab navigation

Article information

22 May 2018
27 Jul 2018
First published
21 Aug 2018

Nanoscale, 2018,10, 16307-16313
Article type

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

R. D. Lin and N. F. Steinmetz, Nanoscale, 2018, 10, 16307
DOI: 10.1039/C8NR04142C

Social activity

Search articles by author